SCHEMBL4569676

SCHEMBL4569676

CCC(=O)N(CCSCCC(=O)O)CCN(CCN(C)C(C)=O)C(C)=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
BHMT Q93088 1/20 0.34
ALDH2 P05091 1/20 0.33
TSHR P16473 1/20 0.30
KDM6B O15054 1/20 0.30
KDM5C P41229 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30
PHF8 Q9UPP1 1/20 0.30
KDM2A Q9Y2K7 1/20 0.30
KDM5A P29375 1/20 0.30
KDM4C Q9H3R0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12601725 0.88 ALDH1A1 (0.46) ALDH1A1HPGDLMNAKMT2AHSD17B10
SCHEMBL22853924 0.82 ALDH1A1 (0.44) ALDH1A1HPGDLMNAKMT2AHSD17B10
SCHEMBL12601755 0.78 ALDH1A1 (0.53) ALDH1A1HPGDLMNAKMT2AHSD17B10
SCHEMBL15495583 0.75 ALDH1A1 (0.41) ALDH1A1HPGDLMNAKMT2AHSD17B10
SCHEMBL4569673 0.75 NOD1 (0.40)
SCHEMBL10050321 0.75 NOD1 (0.40)
SCHEMBL24714503 0.73 ALDH1A1 (0.42) ALDH1A1HPGDLMNAKMT2AHSD17B10
SCHEMBL2735600 0.73 ALDH1A1 (0.42) ALDH1A1HPGDKMT2AHSD17B10TSHR
SCHEMBL24714469 0.71 TSHR (0.47) ALDH1A1HPGDLMNAKMT2AHSD17B10
SCHEMBL28612348 0.70 LMNA (0.56) ALDH1A1HPGDLMNAKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160317673-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS (AL), INC. 2016-11-03 US disclosed
US-9169354-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2015-10-27 US disclosed
US-20150273074-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. 2015-10-01 US disclosed
US-20140066577-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. (US) 2014-03-06 US disclosed
US-8501899-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2013-08-06 US disclosed
US-20120136123-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. (US) 2012-05-31 US disclosed
US-20120123055-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. (US) 2012-05-17 US disclosed
US-8110651-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2012-02-07 US disclosed
US-8101706-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2012-01-24 US disclosed
US-20110009594-A1 MULTIFUNCTIONAL FORMS OF POLYOXAZOLINE COPOLYMERS AND DRUG COMPOSITIONS COMPRISING THE SAME SERINA THERAPEUTICS, INC. (US) 2011-01-13 US disclosed
US-20100330023-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160317673-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same ERBB3, ERBB2, PANK2 ALDH1A1 3859/4885HPGD 1131/4885LMNA 4630/4885
US-20100330023-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same ERBB3, ERBB2, PANK2 ALDH1A1 3859/4885HPGD 1131/4885LMNA 4630/4885
US-20150273074-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same ERBB3, ERBB2, PANK2 ALDH1A1 3805/4885HPGD 1177/4885LMNA 4609/4885
US-20140066577-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same ERBB3, ERBB2, PANK2 ALDH1A1 3859/4885HPGD 1131/4885LMNA 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.